Rynek i konsumenci · 19/02/2002
FDA Proposes Exemption from Child-Resistant Packaging for Hormone Replacement Therapy Products
The US FDA is proposing to exempt hormone replacement therapy (HRT) products containing progestogen or estrogen substances from child-resistant packaging requirements, a move that would uniformly cover all such products
Source: Federal Register — Consumer Product Safety CommissionOpen original release →